News

NineSigma has connected IAVI with some of the biomedical researchers, and helped it identify two scientists who will receive $875,000 to develop solutions for generating stable protein complexes

As per the agreement, Novartis will pay an upfront payment of $34m to Enanta and is even eligible to receive up to $406m if certain clinical, regulatory, and

As per the alliance agreement, Mnemosyne will own all IP generated and is responsible for clinical development and commercialization. The collaboration is expected to focus on developing subunit

The open label, multicenter CATS1 study included 20 patients with severe chronic active Crohn’s disease, who had failed current treatments, including multiple biologics. The Ovasave treatment impacted the

The product is launched under the brand name Trovas in bottles and blister packs, through retail pharmacy chains. Atorvastatin, a cholesterol reducing drug, is the most prescribed statin

The lawsuit requests monetary damages and permanent injunction against importation of infringing materials into the US. Precision claims that Cellectis’ manufacture, use, sale, and importation of certain engineered

Zelboraf is designed to selectively inhibit the BRAF mutation that occurs in about half of all cases of melanoma. Zelboraf and its companion diagnostic, the cobas 4800 BRAF

The randomized, placebo-controlled GEMINI I trial has met primary endpoints of improvements in clinical response in induction and clinical remission in maintenance. In the double-blinded trial, patients were

In January 2012, Dako has entered into a contract with Amgen introducing a new business model which supports the concurrent development of drug and diagnostics for a rare